Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

CSL Pays $102 Million to Acquire Remaining 20% of China's RuiDe Bio

publication date: Jun 22, 2018

CSL Limited of Australia will pay $102 million to buy the remaining 20% in a China plasma company, Wuhan Zhong Yuan Rui De Biological Products (RuiDe). One year ago, CSL acquired an 80% RuiDe stake from China's Humanwell Healthcare Group for $352 million. The companies had a previous relationship: CSL had been supplying RuiDe with albumin for China. With the purchase, CSL became a full-fledged participant in China's plasma collection and products market. More details....

Stock Symbols: (ASX: CSL; USOTC: CSLLY) (SHA: 600079)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.